GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (OTCPK:BLCM) » Definitions » Price-to-Owner-Earnings

Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) Price-to-Owner-Earnings : (As of May. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-05-23), Bellicum Pharmaceuticals's share price is $0.07475. Bellicum Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Bellicum Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

During the past 11 years, the highest Price-to-Owner-Earnings of Bellicum Pharmaceuticals was 180.63. The lowest was 102.50. And the median was 125.63.


BLCM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.52
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-23), Bellicum Pharmaceuticals's share price is $0.07475. Bellicum Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.72. Therefore, Bellicum Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-05-23), Bellicum Pharmaceuticals's share price is $0.07475. Bellicum Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.77. Therefore, Bellicum Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Bellicum Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Bellicum Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Price-to-Owner-Earnings Chart

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bellicum Pharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, Bellicum Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellicum Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's Price-to-Owner-Earnings falls into.



Bellicum Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Bellicum Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.07475/-0.75
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellicum Pharmaceuticals  (OTCPK:BLCM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Bellicum Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.
Executives
Charity Scripture officer: Chief Development Officer C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, STE. 1200, HOUSTON TX 77098
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Stephen Davis director ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Charles S. Grass officer: Principal Accounting Officer C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Richard A. Fair director, officer: President and CEO C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
David Eric Strauss officer: Director, Corporate Controller 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Shane Ward officer: Sr. VP and General Counsel C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Woodard Jr Joseph Paul officer: SVP Clinical & Medical Affairs C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Aaron E. Foster officer: Sr VP, Head of Research C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE 800, HOUSTON TX 77030
Rosemary Y. Williams officer: Principal Accounting Officer 2130 W. HOLCOMBE BOULEVARD, SUITE 800, HOUSTON TX 77030
Judith V Klimovsky director C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Atabak Mokari officer: Sr. VP and CFO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Jon P Stonehouse director 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
David M. Spencer officer: Chief Scientific Officer C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Alan A Musso officer: CFO and Treasurer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139